Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical performance of the novel full-genotyping OncoPredict HPV Quantitative Typing assay using the VALGENT framework.

International journal of cancer - 1 Feb 2024

Cocuzza Clementina Elvezia, Dhillon Sharonjit Kaur, Martinelli Marianna, Giubbi Chiara, Njoku Ruth Chinyere, Bhatia Ramya, Cuschieri Kate, Arbyn Marc

Abstract excerpt

Clinical validation of human papillomavirus (HPV) assays according to international criteria is prerequisite for their implementation in cervical cancer screening. OncoPredict HPV Quantitative Typing (QT) assay (Hiantis Srl, Milan, Italy) is a novel full-genotyping multiplex real-time PCR quantitative assay targeting E6/E7 genes, allowing individual viral load determination of 12 high-risk (HR) HPV types. Quality...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Early Detection of Cancer
Share to Genotyping Techniques

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Papillomaviridae

Share to Papillomavirus Infections

Share to Reproducibility of Results

Share to Sensitivity and Specificity

Share to Uterine Cervical Dysplasia

Share to Uterine Cervical Neoplasms

Source

Identifiers

PMID: 37855030
DOI: 10.1002/ijc.34754

Genes

GP5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical performance of the novel full-genotyping OncoPredict HPV Quantitative Typing assay using the VALGENT framework.PMID 37855030Read ↗

Clinical and Analytical Performance of the BD Onclarity HPV Assay with SurePath Screening Samples from the Danish Cervical Screening Program Using the VALGENT Framework.Semantic proximity Read ↗

Clinical and Analytical Evaluation of the Anyplex II HPV HR Detection Assay within the VALGENT-3 Framework.Semantic proximity Read ↗

Clinical Evaluation of INNO-LiPA HPV Genotyping EXTRA II Assay Using the VALGENT FrameworkSemantic proximity Read ↗

Clinical validation of the Cobas 4800 HPV assay using cervical samples in SurePath medium under the VALGENT4 framework.Semantic proximity Read ↗

Clinical and Analytical Evaluation of the Alinity m HR HPV Assay within the VALGENT-3 Framework.Semantic proximity Read ↗

Evaluation and Optimization of the Clinical Accuracy of Hybribio's 14 High-Risk HPV with 16/18 Genotyping Assay within the VALGENT-3 Framework.Semantic proximity Read ↗

Assessment of the Roche Linear Array HPV Genotyping Test within the VALGENT framework.Semantic proximity Read ↗

Clinical and analytical performance of the PapilloCheck HPV-Screening assay using the VALGENT frameworkSemantic proximity Read ↗

Evaluation of the Clinical Performance of the HPV-Risk Assay Using the VALGENT-3 Panel.Semantic proximity Read ↗

Clinical Performance of the Full Genotyping Agena MassARRAY HPV Assay Using SurePath Screening Samples within the VALGENT4 Framework.Semantic proximity Read ↗

The Valgent4 protocol: Robust analytical and clinical validation of 11 HPV assays with genotyping on cervical samples collected in SurePath mediumSemantic proximity Read ↗

Allplex HPV HR Detection assay fulfils all clinical performance and reproducibility validation requirements for primary cervical cancer screening.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.